Nocturia News and Research

RSS

NAFC holds free educational webinar for seniors who live with incontinence

The National Association For Continence is holding a free educational webinar, Nocturia: Risk Factors for Falls & Fractures and Nighttime Fall Prevention Strategies, on Tuesday, April 20 at 8 p.m. (EST). This event will benefit seniors who live with incontinence and their caregivers.

13 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

CPEX Pharmaceuticals Inc. today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX's patented intranasal drug delivery technology.

2 Apr 2010

Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development

Allergan, Inc. and Serenity Pharmaceuticals, LLC today announced a global agreement for the development and commercialization of Ser-120, a Phase III investigational drug currently in clinical development for the treatment of nocturia, a common yet often under-diagnosed urological disorder in adults characterized by frequent urination at night time.

1 Apr 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

AUA experts urge to focus on urologic health conditions in upcoming year

This new year, make a resolution to improve your health and talk to your doctor about urologic conditions. Although urologic problems may seem embarrassing to talk about, these conditions are more common than you think and a delay in seeking medical attention could cause you unnecessary stress, prolong the problem and even increase your risk for a more serious condition.

30 Dec 2009

Most Canadians hope OAB symptoms will go away

A recent poll conducted by Leger Marketing, on behalf of the Powder Room - a national education program for those with overactive bladder (OAB) - asked 1,500 Canadians about their bladder health. The findings revealed that although people are experiencing OAB symptoms, most are choosing not to seek medical attention - perhaps assuming the frustrating and embarrassing symptoms will go away, or that they will just have to live with them.

23 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

Tru-flo urinary catheter valve from ProtekMed

ProtekMed has launched the Tru-flo(TM) urinary catheter valve, an innovative and economical alternative to the standard tube and bag system prescribed by most urologists today.

26 Oct 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Significantly increased mortality rate in elderly patients with nocturia

Patients suffering from nocturia, the need to urinate at least twice during the night, may have a significantly increased risk for mortality.

7 May 2009

Increased mortality linked to frequent nightime urination

Patients suffering from nocturia, the need to urinate at least twice during the night, may have a significantly increased risk for mortality.

26 Apr 2009

Bladder conditions - raising awareness

November is Bladder Health Month, and there's no better time to raise awareness of the bladder conditions that affect millions of patients, who often suffer in silence with common, treatable symptoms.

4 Nov 2008

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder

Pfizer Inc has announced that the U.S. Food and Drug Administration (FDA) approved Toviaz (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms.

2 Nov 2008

Coping with urinary incontinence

For older adults, increased urinary frequency is fairly common.

26 Sep 2007

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

All physicians involved in the treatment of PBS/IC understand that the placebo effect likely plays a major role in treatment, and is important when evaluating drug trials.

19 Apr 2007

Prevalence of overactive bladder overestimated

According to a recent study overactive bladder is much less common among Finns than earlier research suggests.

11 Feb 2007

Do symptoms correlate with cystoscopic findings in newly diagnosed PBS/IC?

In patients with untreated and newly diagnosed PBS/IC, can one find a correlation between symptoms and cystoscopic findings?

2 May 2006

Alfuzosin may improve double-J stent related symptoms

The first indwelling endoluminal ureteral stent was described over 30 years ago and has since become a routine and indispensable urologic tool. However, the side effects and patient morbidity associated with ureteral stents are not insignificant.

9 Mar 2006